Only one TKI is approved in a first line setting. Joining us from the 2018 Gastrointestinal Cancers Symposium is Dr. Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, describes the different TKI’s and their uses and also the status of sequencing them.
The Use And Sequencing Of Tyrosine Kinase Inhibitors (TKI’s) In Hepatocellular Carcinoma (HCC)
